On May 27, 2021 Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, reported that the company management team will provide a corporate update for the investment community on Friday, June 11th, at 8:00 AM ET, in conjunction with participation at the EHA (Free EHA Whitepaper)2021 Virtual Congress (Press release, Aptose Biosciences, MAY 27, 2021, View Source [SID1234580666]). The event will include an up-to-date review of clinical data available for Aptose’s clinical programs: luxeptinib (CG-806), Aptose’s oral, first-in-class FLT3 and BTK kinase inhibitor in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies; and APTO-253, a first-in-class small molecule MYC repressor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndromes (MDS).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aptose Corporate Update Details
Date & Time: Friday, June 11th, 8:00 AM ET
Participant Webcast Link: LINK
The slides will be available on Aptose’s website here and a recording of the presentation will be archived shortly after the conclusion of the event.
Early clinical data for luxeptinib (CG-806) and APTO-253 also will be presented in posters at the EHA (Free EHA Whitepaper)2021 Virtual Congress, to be held virtually June 9 – 17, 2021. All e-posters will be made available in the Virtual Congress platform on Friday, June 11 at 09:00 CEST / 03:00 ET. The posters also will be available on the presentations page of Aptose website here.
Poster Presentation Details
Title: A Phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory B cell malignancies
Topic: Chronic lymphocytic leukemia and related disorders – Clinical
Final Abstract Code: EP643
Poster Date & Time: Friday, June 11 at 09:00 CEST
Title: A Phase 1a/b dose escalation study of the MYC repressor APTO-253 in patients with relapsed or refractory AML or high-risk MDS
Topic: Acute myeloid leukemia – Clinical
Final Abstract Code: EP452
Poster Date & Time: Friday, June 11 at 09:00 CEST
Abstract Only
Title: A Phase 1a/b dose escalation study of the mutation agnostic BTK/FLT3 inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
Topic: Acute myeloid leukemia – Clinical
Final Abstract Code: PB1391